Refractory Malignant Solid Neoplasm Recruiting Phase 1 Trials for Pevonedistat (DB11759)

IndicationStatusPhase
DBCOND0088735 (Refractory Malignant Solid Neoplasm)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03323034Pevonedistat, Irinotecan Hydrochloride, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or LymphomaTreatment